D-wave Quantum INC 8-K filings
NYSE
D-Wave Quantum Inc. announced the completion of its public warrant redemption, generating approximately $54.6 million in cash proceeds and simplifying its capital structure.
NYSE
D-Wave Quantum Inc. reminds holders of its public warrants that the redemption deadline is November 19, 2025, at a price of $0.01 per warrant.
NYSE
D-Wave Quantum Inc. announced strong third-quarter 2025 financial results, with revenue up 100% year-over-year and a record cash balance of over $836 million.
NYSE
D-Wave Quantum Inc. and BASF announced a joint proof-of-concept project using hybrid-quantum technology to significantly optimize manufacturing workflows, reducing scheduling time from 10 hours to seconds.
NYSE
D-Wave's Advantage2 quantum computer is now operational at Davidson Technologies in Alabama, targeting critical U.S. government and national defense applications.
NYSE
D-Wave Quantum Inc. announced a €10 million contract for an Advantage2 annealing quantum computer in Italy, supporting the Q-Alliance initiative to advance quantum computing education and research.
NYSE
D-Wave Quantum Inc. announced the redemption of all outstanding public warrants, effective November 19, 2025, at $0.01 per warrant, following strong common stock performance.
NYSE
D-Wave Quantum Inc. announced a €10 million agreement with Swiss Quantum Technology SA to deploy an Advantage2 quantum computer in Europe, expanding global access and supporting Italy's Q-Alliance.
NYSE
D-Wave Quantum Inc. was recognized by Fast Company's 2025 Next Big Things in Tech Awards for its 4400+ qubit Advantage2™ quantum computer.
NYSE
D-Wave Quantum Inc. announced its participation as a founder of Q-Alliance, establishing a global quantum hub in Lombardy, Italy, to accelerate scientific discovery and industrial transformation.
NYSE
D-Wave Quantum Inc. and North Wales Police announced a hybrid-quantum application significantly reduced police incident response times and coordination efforts.
NYSE
D-Wave Quantum Inc. announced its first Qubits Japan 2025 conference, driven by an 83% increase in APAC bookings and new customer agreements.
NYSE
D-Wave Quantum Inc. announced robust second quarter 2025 financial results, featuring significant revenue growth and a record cash balance, alongside key advancements in quantum computing technology and partnerships.
NYSE
D-Wave Quantum Inc. announced the promotion of Diane Nguyen to Executive Vice President, Chief Legal Officer, and General Counsel, effective July 31, 2025, with an increased salary and RSU grant.
NYSE
D-Wave Quantum Inc. announced the release of an open-source quantum AI toolkit and demo, enabling developers to integrate quantum computers into machine learning architectures.
NYSE
D-Wave Quantum Inc. announced a new strategic development initiative focused on advanced cryogenic packaging, leveraging NASA JPL expertise to accelerate quantum processor development and scale to 100,000 qubits.
NYSE
A new report by D-Wave Quantum Inc. and Wakefield Research indicates that a majority of business leaders expect substantial returns from quantum optimization, with many planning to integrate the technology into their workflows.
NYSE
D-Wave Quantum Inc. successfully completed its $400 million at-the-market equity offering at an average price of $15.18 per share, significantly boosting its cash balance to approximately $815 million for strategic acquisitions and general corporate purposes.
NYSE
D-Wave Quantum Inc. has announced a memorandum of understanding with Yonsei University and Incheon Metropolitan City to accelerate quantum computing adoption and research in South Korea, including efforts towards acquiring a D-Wave Advantage2 system.
NYSE
D-Wave Quantum Inc. held its annual meeting of stockholders on June 5, 2025, successfully electing Class III directors and ratifying its independent auditor, alongside immediate changes to its Nominating and Governance Committee.
NYSE
D-Wave Quantum Inc. has entered into a sales agreement to potentially sell up to $400 million of its common stock through an at-the-market offering, providing significant financial flexibility for general corporate purposes.
NYSE
8-K: D-Wave Quantum Secures Nearly $96 Million from Warrant Exercises, Bolstering Financial Position
D-Wave Quantum Inc. announced it has received approximately $95.8 million in gross proceeds from the exercise of warrants, significantly bolstering its cash position.
NYSE
D-Wave Quantum Inc. announced it has received approximately $80.5 million from the exercise of 7.0 million warrants, significantly strengthening its financial position.
NYSE
8-K: D-Wave Launches Advantage2 Quantum Computer, Claims Superior Performance Over Classical Systems
D-Wave Quantum Inc. announces the general availability of its Advantage2 quantum computing system, touting its ability to solve complex problems beyond the reach of classical computers.
NYSE
D-Wave's CEO, Dr. Alan Baratz, discussed the company's quantum supremacy demonstration and the high price point of its systems in a recent interview on Fox Business.
NYSE
D-Wave Quantum Inc. announced record quarterly revenue of $15 million, a 509% increase year-over-year, and a record quarter-end cash position of $304.3 million for the first quarter of 2025.
NYSE
D-Wave Quantum Inc. formalizes its executive severance policy and amends employment agreements to align with the new policy, ensuring consistent benefits for key executives upon qualifying terminations.
NYSE
D-Wave Quantum Inc. and Davidson Technologies, Inc. announce the completion of the physical assembly of a D-Wave Advantage2 annealing quantum system at Davidson's headquarters in Huntsville, Alabama, marking a significant step in advancing national security-focused quantum research.
NYSE
D-Wave Quantum Inc. announces initiatives to increase adoption and deployment of its commercial quantum optimization offering, including updates to hybrid quantum solvers and expanded use cases.
NYSE
D-Wave Quantum Inc. announces successful collaborations with Japan Tobacco Inc. and Ford Otosan, demonstrating the real-world applications of quantum computing in drug discovery and manufacturing optimization.